Simponi® (Golimumab) — Anti-TNF Monoclonal Antibody for Inflammatory Arthritis

Once-Monthly Anti-TNF Biologic for Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Simponi® (Golimumab) is a fully human anti-tumour necrosis factor alpha (anti-TNF-α) monoclonal antibody used to treat moderate to severe rheumatoid arthritis (RA), active psoriatic arthritis (PsA), active ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). Simponi is unique among anti-TNF biologics in offering a once-monthly subcutaneous injection — the least frequent dosing schedule of any anti-TNF therapy — significantly improving patient convenience and treatment adherence.

A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Simponi (Golimumab) to hospitals, rheumatology centres, orthopaedic clinics, and pharmacies across India. Manufactured by Janssen Biotech (Johnson & Johnson), Simponi is one of the most important biologic disease-modifying antirheumatic drugs (bDMARDs) available for inflammatory arthritis.

---

What is Simponi (Golimumab)?

Simponi contains Golimumab — a fully human IgG1 kappa monoclonal antibody that specifically binds with high affinity to both soluble and transmembrane forms of human TNF-α. TNF-α is a pro-inflammatory cytokine that plays a central role in the pathogenesis of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis — driving synovial inflammation, joint destruction, and systemic inflammation.

By binding to and neutralising TNF-α, Simponi prevents TNF-α from interacting with its receptors (TNFR1 and TNFR2) — blocking the downstream inflammatory signalling cascade that drives joint inflammation, destruction, and systemic manifestations.

Full prescribing information is available at the FDA label for Golimumab.

---

Clinical Studies and Evidence

GO-FORWARD Trial (Golimumab + MTX in Active RA) Published in Annals of the Rheumatic Diseases (2009), the GO-FORWARD trial demonstrated that Golimumab plus Methotrexate significantly improved ACR20, ACR50, and ACR70 response rates compared to Methotrexate alone in patients with active RA despite MTX therapy — with ACR50 response of 29.4% vs 11.4% for placebo + MTX.

GO-BEFORE Trial (Golimumab + MTX in MTX-Naive RA) Published in Annals of the Rheumatic Diseases (2009), the GO-BEFORE trial demonstrated significant clinical and radiographic benefits of Golimumab + MTX compared to MTX alone in MTX-naive RA patients — with significantly less radiographic progression.

GO-REVEAL Trial (Golimumab in Psoriatic Arthritis) Published in Arthritis & Rheumatism (2009), the GO-REVEAL trial demonstrated Golimumab significantly improved ACR20 response rates (51% vs 9% placebo) and skin psoriasis (PASI75 response) in patients with active PsA.

GO-RAISE Trial (Golimumab in Ankylosing Spondylitis) Published in Annals of the Rheumatic Diseases (2008), the GO-RAISE trial demonstrated Golimumab significantly improved ASAS20 response rates (59% vs 22% placebo) and reduced spinal inflammation on MRI in patients with active AS.

Long-Term Extension Studies Multiple 5-year extension studies confirm sustained clinical and radiographic benefits of Golimumab across all indications — with consistent safety profile over long-term use.

---

Available Strengths

Simponi is available in the following strengths:

• 50mg/0.5mL — prefilled syringe and SmartJect autoinjector — for RA, PsA, AS, nr-axSpA
• 100mg/1mL — prefilled syringe — for ulcerative colitis and higher dose requirements

The standard subcutaneous dose for RA, PsA, and AS is 50mg once monthly. Simponi is also available as an intravenous formulation (Simponi Aria) at 2mg/kg for RA.

---

Indications — What Simponi is Used For

Rheumatoid Arthritis (RA):

• Moderate to severe active RA in combination with Methotrexate
• In patients with inadequate response to conventional DMARDs

Psoriatic Arthritis (PsA):

• Active psoriatic arthritis — with or without Methotrexate
• Improves both joint and skin manifestations

Ankylosing Spondylitis (AS):

• Active ankylosing spondylitis in adults

Non-Radiographic Axial Spondyloarthritis (nr-axSpA):

• Active nr-axSpA with objective signs of inflammation on MRI or elevated CRP

Ulcerative Colitis (UC):

• Moderately to severely active ulcerative colitis — induction and maintenance

For detailed indication information refer to MedlinePlus Golimumab.

---

Key Benefits of Simponi

Once-Monthly Dosing — Most Convenient Anti-TNF Simponi’s once-monthly subcutaneous injection is the least frequent dosing schedule among anti-TNF biologics — significantly more convenient than Adalimumab (every 2 weeks) and Etanercept (weekly) — improving patient adherence and quality of life.

Fully Human Antibody — Lower Immunogenicity Being fully human, Golimumab has lower immunogenicity compared to chimeric (Infliximab) or humanised antibodies — reducing the risk of anti-drug antibody formation and loss of efficacy over time.

Active Against Both Soluble and Transmembrane TNF-α Golimumab binds both soluble and membrane-bound TNF-α — providing comprehensive TNF blockade that may translate to clinical advantages in certain patients.

Proven Radiographic Protection GO-BEFORE and GO-FORWARD trials demonstrate Simponi significantly reduces radiographic progression — protecting joint structure and preventing long-term disability in RA.

Dual Benefit in Psoriatic Arthritis Simponi improves both joint and skin manifestations of psoriatic arthritis — reducing joint inflammation while also achieving meaningful PASI (Psoriasis Area Severity Index) improvements.

SmartJect Autoinjector The SmartJect autoinjector enables convenient self-administration — with a hidden needle design reducing injection anxiety and improving the injection experience.

---

How Simponi Works

TNF-α is a master pro-inflammatory cytokine produced primarily by macrophages and T cells in response to inflammatory stimuli. In RA, PsA, and AS, dysregulated TNF-α drives:

• Synovial macrophage and fibroblast activation — producing inflammatory mediators
• Neutrophil recruitment and activation in synovial fluid
• Osteoclast activation — driving bone and cartilage destruction
• Endothelial activation — promoting angiogenesis and leucocyte migration
• Systemic inflammation — fatigue, anaemia of chronic disease, cardiovascular risk

Simponi works by:

• Binding with high affinity to both soluble TNF-α and transmembrane TNF-α
• Preventing TNF-α from binding to TNFR1 and TNFR2 receptors
• Blocking downstream NF-κB activation and pro-inflammatory gene expression
• Reducing synovial inflammation, angiogenesis, and osteoclast activation
• Inhibiting cartilage and bone destruction
• Reducing systemic inflammatory burden

For a detailed mechanism overview refer to the European League Against Rheumatism (EULAR) guidelines and American College of Rheumatology (ACR) guidelines.

---

Simponi vs Other Anti-TNF Biologics

---

Dosage and Administration

Rheumatoid Arthritis:

• 50mg SC once monthly — on the same date each month
• Always in combination with Methotrexate

Psoriatic Arthritis:

• 50mg SC once monthly — with or without Methotrexate

Ankylosing Spondylitis / nr-axSpA:

• 50mg SC once monthly

Ulcerative Colitis:

• Induction: 200mg SC at week 0, then 100mg at week 2
• Maintenance: 100mg SC every 4 weeks

Administration:

• Subcutaneous injection — abdomen, thigh, or upper arm
• Rotate injection sites — avoid areas with bruising, redness, or scarring
• Allow prefilled syringe or SmartJect to reach room temperature — 30 minutes before injection
• Do not shake

Full dosing guidelines available at Drugs.com Golimumab Dosage.

---

Pre-Treatment Screening — Essential Before Starting Simponi

All patients must be screened before initiating Simponi:

• Tuberculosis (TB) — Screen with TST or IGRA + chest X-ray. Treat latent TB before starting. Monthly TNF inhibitors have higher TB reactivation risk than intermittent IV biologics
• Hepatitis B — Screen HBsAg, anti-HBc, anti-HBs. HBsAg positive patients require antiviral prophylaxis
• HIV — Consider screening in high-risk patients
• Full blood count — Baseline haematological assessment
• Liver function tests — Baseline assessment
• Malignancy history — Carefully evaluate benefit-risk in patients with prior malignancy

---

Who Should Use Simponi

Simponi is prescribed for:

• Adults with moderate to severe RA with inadequate response to MTX or other conventional DMARDs
• Adults with active PsA with inadequate response to conventional DMARDs
• Adults with active AS or nr-axSpA with inadequate response to NSAIDs
• Adults with moderately to severely active UC with inadequate response to conventional therapy
• Patients where once-monthly dosing is clinically preferred for adherence

Simponi is prescribed by rheumatologists, dermatologists, and gastroenterologists. A.K. Pharma supplies Simponi to hospitals, rheumatology centres, and pharmacies across Delhi and India.

---

Possible Side Effects

Common side effects include upper respiratory tract infections, nasopharyngitis, injection site reactions, and elevated liver enzymes.

Serious side effects include:

• Serious infections including TB reactivation, bacterial sepsis, invasive fungal infections
• Malignancy — increased risk of lymphoma and other cancers with long-term TNF inhibitor use
• Heart failure — may worsen existing heart failure — avoid in NYHA Class III-IV
• Demyelinating disorders — rare cases of new or worsening demyelination
• Lupus-like syndrome — rare
• Hepatitis B reactivation — monitor in carriers

Full side effect information available at FDA Golimumab Safety Information.

---

Precautions

• Screen for latent TB and treat before starting — mandatory
• Screen for Hepatitis B — consider prophylaxis in carriers
• Do not initiate in patients with active infections
• Do not use with other biologics or Jak inhibitors — increased infection risk
• Avoid live vaccines during treatment
• Monitor for signs of infection throughout treatment
• Use with caution in patients with history of malignancy
• Avoid in patients with moderate to severe heart failure (NYHA Class III-IV)
• Monitor for demyelinating disorders — discontinue if confirmed
• Refer to EULAR recommendations for biological therapy for complete management context

---

Storage and Handling

• Store in refrigerator between 2°C and 8°C
• Do not freeze
• Protect from light — keep in original carton
• Allow to reach room temperature before injection — approximately 30 minutes
• Do not use heating devices
• Single use prefilled syringe or SmartJect autoinjector — discard after use

As a responsible medicine distributor in Delhi, A.K. Pharma maintains full cold chain requirements during storage and supply of Simponi ensuring product integrity for every unit supplied.

---

Manufacturer Information

Simponi (Golimumab) is manufactured by Janssen Biotech Inc., a Johnson & Johnson company, in collaboration with MSD (Merck). Golimumab received FDA approval in April 2009 for RA, PsA, and AS. A.K. Pharma supplies only genuine Simponi sourced from authorized Janssen distributors.

---

Related Immunosuppressant and Arthritis Medicines Available at A.K. Pharma

• Scapho (Secukinumab) — anti-IL-17 biologic for psoriasis, PsA, and AS
• Betrecep (Abatacept) — T-cell costimulation inhibitor for RA
• Dupixent (Dupilumab) — anti-IL-4/IL-13 biologic for atopic dermatitis
• Browse all Immunosuppressant Medicines available at A.K. Pharma
• Browse all Arthritis Medicines available at A.K. Pharma

---

Frequently Asked Questions

Q. What is Simponi used for? Simponi (Golimumab) is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and ulcerative colitis. More information available at MedlinePlus.

Q. What is the generic name of Simponi? The generic name of Simponi is Golimumab. It is a fully human anti-TNF-α monoclonal antibody belonging to the biologic DMARD class of medicines.

Q. How often is Simponi injected? Simponi is injected subcutaneously once monthly — on the same date each month. This is the least frequent dosing schedule among anti-TNF biologics — significantly more convenient than Adalimumab (every 2 weeks) or Etanercept (weekly).

Q. Does Simponi need to be used with Methotrexate? For rheumatoid arthritis Simponi must be used in combination with Methotrexate. For psoriatic arthritis and ankylosing spondylitis it can be used with or without Methotrexate.

Q. Is TB screening required before starting Simponi? Yes. All patients must be screened for latent tuberculosis before starting Simponi using TST or IGRA plus chest X-ray. Latent TB must be treated before initiating Simponi.

Q. Is Simponi available in India? Simponi can be supplied to hospitals, rheumatology centres, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.

Q. What is the price of Simponi in India? Simponi price in India varies by strength and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.

Q. How to order Simponi from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.

Q. Does A.K. Pharma supply Simponi in bulk? Yes. A.K. Pharma supplies Simponi in bulk to hospitals, rheumatology centres, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.

---

Why Order Simponi from A.K. Pharma?

• Licensed medicine distributor in Delhi with all required drug licenses
• 100% genuine Simponi sourced from authorized Janssen distributors
• Cold chain maintained throughout storage and delivery
• Bulk supply available for hospitals and rheumatology centres
• Prompt response to all quote requests
• Serving rheumatologists and specialists across Delhi NCR and India

---

Contact A.K. Pharma for Simponi Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in